Research
Adherence
Lifestyle interventions alone are difficult to maintain long-term for weight loss in patients with T2DM and CKD, whereas GLP-1 RAs offer a pharmacological alternative with proven metabolic and organ protection benefits.
While lifestyle changes are important, they are hard to keep up long-term. GLP-1 RAs can help you maintain weight loss and protect your heart and kidneys, making it easier to stick to healthy habits. Talk to your doctor about whether a GLP-1 RA is right for you.
GoodQualifiesHIGH confidence
However, the fundamental challenge of treating obesity solely with ‘lifestyle interventions’ is the difficulty of maintaining these changes over time.
Why this rating
Based on the Look AHEAD trial analysis and general clinical experience discussed in the review.
Source
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Daria Abasheva et al. · Clinical Kidney Journal · 2024
DOI 10.1093/ckj/sfae296
narrative_reviewCited 45×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) provide cardiovascular and kidney protection in patients with chronic kidney disease (CKD) and overweight/obesity, with or without type 2 diabetes (T2DM), by reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression.Strong
- GLP-1 RAs reduce blood pressure and albuminuria in patients with CKD and overweight/obesity, contributing to kidney and cardiovascular protection.Good
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →